Form 4: Shuttle Pharmaceuticals CFO Acquires 100,000 Shares of Common Stock

Michael Vander Hoek, CFO of Shuttle Pharmaceuticals Holdings, Inc., acquired 100,000 shares of common stock on March 8, 2024.

Summary

• On March 8, 2024, Michael Vander Hoek, the Chief Financial Officer of Shuttle Pharmaceuticals Holdings, Inc., acquired 100,000 shares of the company's common stock.
• The acquisition was a direct transaction.
• The price per share was $0.00.
• Following the transaction, Vander Hoek directly owns 103,852 shares of Shuttle Pharmaceuticals Holdings, Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisition by a company insider. While insider buying can be seen as a positive signal, without additional context, it's difficult to gauge the overall impact.

Positives

• The CFO's acquisition of a significant number of shares could be interpreted as a positive signal about the company's prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders.

Stakeholder Impact

• The acquisition of shares by the CFO may increase investor confidence.

Key Dates

Keywords

Form 4, Beneficial Ownership, Michael Vander Hoek, Shuttle Pharmaceuticals, SHPH, Common Stock, Acquisition, CFO